Compare DexCom, Inc. (DXCM) vs Navan Inc. Class A Common Stock (NAVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Navan Inc. Class A Common Stock — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Navan Inc. Class A Common Stock trades at $23.63 (market cap $6.01B). The key difference: DexCom, Inc. is far larger — about 5.3× Navan Inc. Class A Common Stock's market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 2,990,425). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Navan Inc. Class A Common Stock for 1 Days on average.
| DXCM | NAVN | |
|---|---|---|
Market Cap | $31.86B | $6.01B |
Volume | 3,607,070 | 2,990,425 |
Sector | Health | Technology |
52-Week High | $92.34 | $30.58 |
52-Week Low | $54.84 | $8.51 |
Typical Hold Time | 62 Days | 1 Days |
Enterprise Value | $31.32B | $5.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.11, down 0.23% on the day, with a bearish technical signal but strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating expectations, and has shown consistent revenue growth, with 2025 revenue reaching $4.66 billion and net income of $836.3 million. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target. Recent news highlights growth opportunities in Type 2 diabetes care and key executive promotions.
The outlook for DXCM is positive due to robust earnings beats, expanding market opportunities, and strong institutional support. However, risks include competitive pressures, reimbursement challenges, and a high valuation with a P/E of 33.38. The stock presents a growth opportunity but requires monitoring of execution against these risks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Navan Inc. Class A Common Stock
Navan provides an AI-powered platform for business travel, payments, and expense management. Its tools support trip booking, policy controls, payment processing, expense reconciliation, and reporting.
Read more on NAVN →
